Objectives: The introduction of new rotavirus vaccines into the public sphere makes it necessary to maintain constant surveillance and to heighten public awareness of the appearance of new rotavirus strains. We describe the molecular epidemiology of circulating rotavirus strains after vaccine introduction. Methods: We collected a total of 1070 stool samples from children with gastroenteritis from January 2013 to June 2013. The antigenic prevalence of rotavirus group A was distinguished using enzyme immunoassay. The G and P genotypes of enzyme immunoassay-positive samples were determined with reverse transcription-polymerase chain reaction and nucleotide sequencing analysis. Results: Of the 1070 samples collected, 277 (25.9%) tested positive for rotaviruses by enzyme-linked immunoabsorbent assay. The most prevalent circulating genotype G was G1 (51.3%), followed by G2 (34.7%) and G9 (10.8%). The predominant type of genotype P was P[8] (66.1%), followed by P[4] (31.4%). In this study, nine genotypes were found. G1P [8] Conclusion: Molecular epidemiological knowledge of rotaviruses is critical for the development of effective preventive measures, including vaccines. These data will help us monitor the effectiveness of current rotavirus vaccines.
Introduction
Rotaviruses (RVs) are the leading cause of acute and severe gastroenteritis, diarrhea, and malnutrition primarily in children younger than 5 years [1] , and are responsible for approximately 600,000 deaths worldwide each year [2, 3] .
RVs belong to the family Reoviridae. The viral genome consists of 11 segments of double-stranded (ds) RNA genome that encodes six structural proteins (VP1e4, VP6, and VP7) and six nonstructural proteins (NSP1e6) [1] . So far, RVs are subdivided into eight groups (AeH) on the basis of the antigenic properties or the amino acid sequences of the inner capsid protein VP6 [4] .
Based on the differences of VP7 and VP4 gene sequences, RVs are divided into genotypes G and P, respectively. To date, at least 27 G and 35 P genotypes have been reported from humans and a variety of mammalian and avian species [5] . Of these, 11 G genotypes and 12 P genotypes have been isolated from humans [6e8]. However, the most commonly isolated human RV genotypes are a small number of combined G/P genotypes, such as G1P [8] , G2P [4] , G3P [8] , G4P [8] , and G9P [8] [8, 9] . Certain G and P types have been found to be highly prevalent in different areas around the world such as G5 types in Brazil and G10 types in India [10, 11] . More recently, a surveillance program directed by the World Health Organization noted that in 2010 the predominant uncommon strains were G12P [8] and G12P [6] viruses in Southeast Asia; G2P [6] , G3P [6] , and G1P [6] viruses in sub-Saharan Africa; G1P [4] and G2P [8] viruses in the Western Pacific; and G9P [4] viruses in the Americas [9] .
In South Korea, molecular epidemiological studies have shown that G2, G4, and G9 were the most isolated genotypes from 1998 to 2004. G1 was the most predominant genotype from years 1987 to 1999, and genotypes G2, G3, and G4 were also isolated during the same period [12] . G11, a rare strain, was also reported for the first time in South Korea in 2007 [13] . Recently, there have been changes in the frequency of genotype isolations from more common G/P combinations with the exceptions of G1P [8] and G3P [8] to the rare combinations of genotypes such as G4P [6] and G2P [8] [14] . These distinct changes in the prevalence of circulating RV strains suggest that surveillance studies are important for the successful vaccine development and efficacy testing.
Even with the ongoing vaccinations against RVs, RV infection with high morbidity and mortality occurs. This indicates that we should take into account the role of RV vaccines in the natural temporal variability in genotypes G and P. Two live attenuated RV vaccines were licensed and became commercially available in South Korea. RotaTeq (Merck & Company, Inc, Whitehouse Station, NJ, USA), launched in September 2007, is a vaccine that consists of five distinct bovine reassortants, and each of the five vaccine strains contains outer capsid proteins from a serotype of the human RVs (G1, G2, G3, G4, and P [8] ). Rotarix (GlaxoSmithK-line, Rixensart, Belgium), licensed in June 2008, consists of a single attenuated G1P [8] strain of human RV.
The effect of RV vaccines on the natural pattern of circulating RV strains in human populations is unknown and difficult to predict. Continuing surveillance is needed to identify the spectrum of protection engendered by each vaccine and the effect that each vaccine may have on circulating strains. Documentation of long-term temporal changes in RV strain distributions requires a detailed analysis of targeted monotypes in circulation prior to and after vaccine introduction.
In this study, we report the distribution of RV genotypes G and P that have been circulated during the first half of 2013 in Gwangju, South Korea.
Materials and methods

Sample collection
From January 2013 to June 2013, a total of 1070 stool samples were collected from children who were hospitalized with acute gastroenteritis symptoms in eight hospitals, Gwangju, South Korea. Samples were kept at 4 C until they were transported to the laboratory for analysis. Clinical information on age and sex of patients, dates of disease onset and sample collection, symptoms, RV vaccination history, etc., was recorded as background data.
RV antigen detection
RV antigens were detected in stool supernatants using enzyme-linked immunoabsorbent assay (ELISA) with VP6 group-specific antibody (BioTracer Rotavirus ELISA kit; Biofocus, Uiwang, Korea) according to the manufacturer's instructions. Specimens with Optic Density (OD) absorbance values >0.4 at a 450-nm wavelength were considered to be positive.
Reverse transcription-polymerase chain reaction for genotyping
G and P genotyping was performed using reverse transcription-polymerase chain reaction (RT-PCR) on 277 RV ELISA positive samples. Fecal specimens were diluted 1:10 in phosphate-buffered saline. After a thorough mixing, each fecal suspension was centrifuged for 20 minutes at 1000 Â g, 4 C. RV ds RNA was extracted from 140 mL of 10% fecal suspensions using an RNA extraction Kit [QIAamp Viral RNA mini Kit (spin protocol); Qiagen, Inc., Hilden, Germany] in accordance with the manufacturer's instructions. The extracted RNA was denaturated at 95 C for 5 minutes. RT-PCR was performed for RV G and P genotypes using Accupower Hotstart RT/PCR premix kit (Bioneer, Daejeon, Korea). We amplified an 881-bp fragment of the VP7 gene with the consensus forward primer VP7-F (5 0 -ATG TAT GGT ATT GAA TAT ACC AC-3 0 ) and reverse primer VP7-R (5 0 -AAC TTG CCA CCA TTT TTT CC-3 0 ) [15] . We also amplified an 876-bp fragment of the VP4 gene with the consensus forward primer Con3 (5 0 -TGG CTT CGC CAT TTT ATA GAC A-3 0 ) and the reverse primer Con2 (5 0 -ATT TCG GAC CAT TTA TAA CC-3 0 ) [16] . The PCR reaction for the VP7 and VP4 gene amplification Diversity of circulating rotavirus strainswas carried out with an initial RT step at 42 C for 40 minutes, followed by PCR activation at 94 C for 15 minutes, then 35 cycles of amplification (1 minute at 94 C, 1 minute at 50 C, and 1 minute at 72 C), and a final extension of 10 minutes at 72 C in GeneAmp PCR system 9700 (Applied Biosystems, Boston, MA, USA). The PCR products were then electrophoresed on 1.5% agarose gel.
Nucleotide sequencing and sequence analysis
PCR products were purified using QIAquick Gel Extraction kit (Qiagen GmbH, Hilden, Germany) in accordance with the manufacturer's instructions. The cycle sequencing reaction was carried out with the ABI PRISM BigDye terminator cycle sequencing reaction kit (Applied Biosystems, Foster City, CA, USA), and sequence data were collected by means of an automated DNA analyzer Applied Biosystems (ABI) Prism 3100 Genetic Analyzer (Life Technologies, Foster City, California, USA). Phylogenetic analysis was performed using the Clustal W algorithm in MEGA 5.0 software package [17] , using the Maximum Likelihood method for phylogenetic analysis, with 1000 bootstrap replicates.
Results
Frequency of RV infection by vaccination status
Overall, 774 of 1070 patient records clearly stated the status of the vaccination, and the previously vaccinated patients were vaccinated either with RotaTeq or with Rotarix. Sixty-seven (17.4%) of the 385 vaccinated patients were infected with RVs, compared to the infection of 144 (37%) of 389 patients who did not receive the vaccine (Table 1) . Statistical significance in two tests was assessed. A p value of <0.05 was considered indicative of a statistically significant difference. All analyses were performed using IBM SPSS statistics 20 (IBM Korea, Seoul, Korea).
Frequencies of G and P genotypes
RVs were detected in 277 of 1070 (25.9%) collected samples. Two hundred of 277 (86.6%) patients with RV gastroenteritis were older than 5 years. The G genotype was identified for 274 samples (98.8%), and the P genotype was identified for 272 (98.2%) RV samples. The most prevalently circulating G genotype was G1 (51.3%, n Z 142), followed by G2 (34.7%, n Z 96), G9 (10.8%, n Z 30), G3 (1.8%, n Z 8), and G4 (0.4%, n Z 1). The predominant type of P genotype was P [8] (66.1%, n Z 183), which was followed by P [4] (31.4%, n Z 87), P [6] , and P [9] (0.4%, n Z 1) ( Figure 1, Table 2 ).
Distribution of G and P genotype combinations
In total, 272 G and P combinations made up with nine different genotypes were identified. G1P [8] , the most frequently detected strain, was responsible for 51.8% (n Z 141) of infections. G2P [4] , G9P [8] , and G2P [8] were detected with a prevalence rate of 30.5% (n Z 83), 9.9% (n Z 27), and 4.0% (n Z 11), respectively. In addition, unusual RV strains were identified, which bore the genotypes of G1P [4] , G3P [9] , G3P [8] , G4P [6] , and G9P [4] (Table 3) . Among the 67 patients who were vaccinated with RV, the predominant strain was G2P [4] (40.3%), followed by G1P [8] (39.0%) and G9P [8] (12.5%). And among the 389 who were not vaccinated, 144 rotavirus positive samples were analyzed, and the 
Discussion
RVs are composed of genetically diverse populations of segmented ds RNA viruses, which cause gastroenteritis in many animal species including humans. From year to year and from place to place, the prevalence of human RV G and P types associated with the disease fluctuates [18] .
In the present study, the distribution of the genotype of Group A RVs in the cases of acute gastroenteritis in Gwangju, South Korea, was investigated to determine the efficacy of currently used RV vaccines in South Korea.
In our study, 1070 fecal specimens were collected from children hospitalized with diarrhea, and 277 (25.9%) were positive for RV. A nationwide surveillance of RV infection conducted by 16 increased by more than three times when compared with the previous year in Gwangju, South Korea.
One of the main goals of this study was to characterize the VP7 (G genotype) and VP4 (P genotype) genes from RVs circulating in public. The predominant G genotype was G1 (51.3%), followed by G2 (34.7%) and G9 (10.8%). G2 and G4 RVs were the most frequently detected genotypes out of the four common strains (G1eG4) between 1998 and 2004 [20] . G1 was the most predominant strain for a 10-year period prior to 1997 and during 2005e2009 in South Korea [14] . Recently, human G9 strains became the fifth most common strain found in the public sphere [21] . The first G9 strain, WI91, was detected in children in the United States in 1983 [22] and was first detected in 2002 in South Korea [14] . G9 has become recognized as one of the emerging genotypes in many countries such as Cuba [23] , France [24] , Mexico [25] , the United States [26] , and Libya [27] . In this study, G9s were the third most identified genotype and had a slightly greater predominance over G3 and G4. These results suggest that the genotype G9 should be considered one of the serotypes of choice for RV vaccines in the future. P [8] (66.1%) was the most common genotype P, followed by P [4] (31.4%), P [6] , and P [9] (0.1%). This result is in agreement with previous data stating that P [8] was the most prevalent strain in Korea and other countries [12, 28] . Genotypes P [6] and P [9] were detected less frequently; however, these uncommon types continue to be of interest because of a possible agent in RV vaccine programs.
Regarding GeP combinations, the G1P [8] (51.8%) genotype combination was the most prevalent RV type followed by G2P [4] (30.5%) in 2013. Previous studies [14] . The prevalence of G2P [4] was 34.6% in 2000e2001 [29] . Recently, an increase in the incidence of infection with the G2P [4] strain has been reported in Brazil, where the monovalent G1P [8] vaccine is currently in use [30] . Also, reassortants of common human strains, G9P [4] and G1P [4] , and a zoonotic genotype G4P [6] were also identified in south Korea [29] . These studies suggest that the distribution of circulating RV genotypes and predominant strains changes from year to year and has been reported to differ in different regions. Moreover, there are reassortments between human RVs (P [8] and P [9] ) or between human and animal strains. Therefore, continuing surveillance is important to monitor the changes in virus genotype patterns and the appearance of new genotypes in each country.
There were slight differences in the genotype distribution in the patient groups with or without prior vaccination. We conclude that the prevalence of specific RV genotypes in a region changes each year, and nonvaccine strains such as G9, P [4] , P [6] , and P [9] have increased in Gwangju, South Korea. These emerging strains should be considered as candidates for new RV vaccines in the future.
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